Share us 

  • Facebook - Grey Circle
  • Twitter - Grey Circle
  • Google+ - Grey Circle
  • Instagram - Grey Circle

© 2018 TSI Inc. 

Leadership

Management

 

Alexis Wallace has over 20 years of international business development and operational experience, including more than two decades with leading biopharmaceutical companies and ventures. Prior to joining TSI, Mr. Wallace was Executive Director of Medicine in Need, a not-for-profit biotechnology company funded by the Bill and Melinda Gates Foundation. There, Mr. Wallace oversaw the development of an inhaled version of an anti-tuberculosis drug from pre-IND through phase I human clinical trials. Mr. Wallace was also a Principal in the Business Development arm of Puretech Ventures, where he created and grew the company’s European business. Mr. Wallace also served as the Director of Science Strategy at Genzyme Corporation, where he was instrumental in the establishment of major joint ventures resulting in three commercialized products. Mr. Wallace holds an undergraduate degree in Life Sciences from Université Pierre et Marie Curie, Paris, France; an MScEng in Organic Chemistry from École Supérieure de Chimie Industrielle de Lyon, France; and an MBA from the Tuck Business School at Dartmouth College. Mr. Wallace is a member of the Board of Directors of the Vascular Laboratory, Inc.

President and Chief Executive Officer, Director and Co-founder

Alexis C. Wallace, MScEng, MBA

Victor Gurewich is a preeminent expert in fibrinolysis and has conducted world- leading research in this area for over 40 years. Dr. Gurewich was co-director of the first clinical trial of streptokinase (SK) in the U.S., then subsequently served as a consultant to Hoechst-Roussel to help gain SK regulatory approval.  In 1979, Dr. Gurewich co-discovered and licensed prourokinase (proUK), the single chain form of urokinase. He was then involved with several clinical trials in the U.S. and Europe, exploring the use of proUK in heart attack and deep vein thrombosis. Dr. Gurewich also served on the National Institutes of Health (NIH) consensus panel for thrombolytic therapy in 1980, and led the design and supervised the ProUK and t-PA Enhancement of Thrombolysis (PATENT) trial in the mid 1990s. Additionally, Dr. Gurewich’s team developed proUK’s M5 mutation, or HisproUK – now being developed by TSI. Dr. Gurewich is Professor of Medicine at Harvard Medical School, a Director of the Vascular Research Laboratory, Inc., and a practicing physician at Mount Auburn Hospital, in Cambridge, Mass.

Chief Scientific Officer, Director and Co-founder

Victor Gurewich, MD

Board of Directors

 

In addition to Mr. Wallace and Dr. Gurewich, the following life sciences leaders sit on the TSI Board of Directors. 

Michael Woehler has more than 40 years of experience in business management. He has overseen operations, finance, marketing and business development as well as global P&L responsibility for multiple clinical and life science companies. Among other leadership positions, Dr. Woehler served as President and CEO of CoreLab Partners, Inc., a worldwide leader in cardiac safety and imaging services; Executive Vice President of PAREXEL International Corporation, one of the largest contract life sciences and pharmaceutical outsourcing organizations in the world; and President of the North American Holding Company of Amersham Pharmacia Biotech. Dr. Woehler holds a B.A. in Biology/Chemistry from Northwestern University and a Ph.D. in Microbiology/Immunology from Marquette University.

Non-Executive Chairman

Michael Woehler, PhD

Annalisa Jenkins currently serves as the CEO of U.K.-based PlaqueTec – a company pioneering biomarker-based strategies to routinely assess inflammation in the coronary artery and identify those at highest risk of heart attack. Dr. Jenkins was previously President and CEO of Dimension Therapeutics, a leading gene therapy company that was acquired by Ultragenyx in November 2017. Dr. Jenkins served in R&D leadership roles at Merck Serono and Bristol Myers-Squibb, where she became head of Global Medical Affairs over her 15-year tenure. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. She also is a committee member of the Science Board to the U.S. Food & Drug Administration (FDA), and chairs or serves on the boards of a number of private and public biotech and life science companies. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital at the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.

Non-Executive Board Member

Annalisa Jenkins, MBBS, FRCP

Clinical Advisory Board

 

Greogory del Zoppo is a fellow of the American Heart Association/American Stroke Association and chairs the Brain Injury and Neurovascular Pathologies Section at the NIH. Dr. del Zoppo, a pioneer of acute thrombolysis in ischemic stroke, has published widely on therapeutic interventions for cerebral stroke and is a frequent editorialist for the journals Stroke and Nature Medicine. He has consulted for a variety of pharmaceutical and biotechnology companies including Abbott Laboratories, Amgen, Biogen Idec, Boehringer Ingelheim GmbH, Burroughs Wellcome, Genentech, ICOS Corp., and SmithKline Beecham. Dr. del Zoppo has participated in numerous clinical trials in acute ischemic stroke. He was organizer, principal investigator and chairman of the steering committee for TTATTS; organizer, principal investigator and chairman of the executive/steering committee for PROACT; and member of the safety committees for ECASS and ECASSII, among other pivotal studies.

Professor of Medicine (Hematology) & Adjunct Professor of Neurology, Washington University

Gregory J. del Zoppo, M.D.,

James Muller founded InfraReDx in 1998 to develop spectroscopic technology to identify lipid core plaques, which are suspected to be vulnerable plaques. In 2005, he left his position as professor of medicine at the Harvard Medical School to serve as CEO of InfraReDx during the development of the scientific foundation of the lipid core plaque instrument. He is the author of over 300 manuscripts related to coronary artery disease, the leading cause of death in the developed world. Dr. Muller was formerly the chief of cardiology at Beth Israel Deaconess Medical Center, Boston. Dr. Muller was one of three American co-founders of the International Physicians for the Prevention of Nuclear War (IPPNW), which was awarded the 1985 Nobel Peace Prize.

Founder, Former Chief Medical Officer and Chairman, InfraReDx

James E. Muller, M.D.,

C. Michael Gibson is an interventional cardiologist, cardiovascular researcher and educator who pioneered life saving procedures in the treatment of heart attacks. Dr. Gibson founded and led his own Academic Research Organization (PERFUSE) for 30 years, and has been a leading investigator in more than 120 clinical trials of numerous cardiovascular drugs and devices. Under Dr. Gibson's direction, PERFUSE created the master database that unified data from over many years of TIMI studies (TIMI 1-50) in nearly 100,000 patients and coordinated data analyses for the TIMI study group. In addition to his post as President & CEO of the Baim Institute, Dr. Gibson serves as Professor of Medicine, Harvard Medical School; Interventional Cardiologist, Beth Israel Deaconess Medical Center. Dr. Gibson has been frequently chosen as one of Boston's Top Doctors & U.S. News & World Report also lists Gibson as one of America's top doctors.   

President & CEO, Baim Institute for Clinical Research

C. Michael Gibson, M.D.

Arthur Sasahara is currently co-director of the Venous Thromboembolism Research Group at Brigham and Women’s Hospital. Previously, Dr. Sasahara served as senior physician, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, and Professor of Medicine, Emeritus, Harvard Medical School. He also held the positions of Chief of Cardiology and Chief of Medicine at the Harvard-affiliated West Roxbury Veterans Affairs Medical Center for almost 30 years. In 1987, Dr. Sasahara joined Abbott Laboratories as the first venture head, Thrombolysis Research, subsequently becoming senior venture head (1993) and senior medical consultant, Research and Development, Pharmaceutical Products Division (1995). Dr. Sasahara’s publications include approximately 300 scientific papers and six books.  He obtained his medical degree from Case Western Reserve University School of Medicine and his Residency in Internal Medicine and Cardiology at Tufts, Harvard, and Yale University hospitals.

Professor of Medicine Emeritus, Harvard Medical School, Brigham and Women’s Hospital

Arthur Sasahara, M.D.

  • White LinkedIn Icon
  • White Twitter Icon